We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Jackson ImmunoResearch Launches Secondary Antibodies for VHH Discovery
Product News

Jackson ImmunoResearch Launches Secondary Antibodies for VHH Discovery

Jackson ImmunoResearch Launches Secondary Antibodies for VHH Discovery
Product News

Jackson ImmunoResearch Launches Secondary Antibodies for VHH Discovery

Image credit: Jackson ImmunoResearch

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Jackson ImmunoResearch Launches Secondary Antibodies for VHH Discovery"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Jackson ImmunoResearch, manufacturer of secondary antibodies for the life science market, announces a new range of products for scientists developing single-domain VHH antibodies.

The new Anti-Alpaca secondary antibody product line targets the IgG repertoire of camelid immunoglobulins, including whole molecule, subclass and VHH domain specificities. They are raised against alpaca and cross-react with llama.

Anti-Alpaca IgG subclasses 2+3 specific antibodies enable scientists to monitor immune response and pinpoint the optimal B cell harvest timeframe. Anti-Alpaca VHH domain antibodies were also developed to detect single-domain antibodies across all immunotechniques and will be an indispensable tool in diagnostics and drug development.

David A. Fancy PhD, chief operating officer, commented “Jackson ImmunoResearch is very excited to bring anti-camelid secondary antibodies to the marketplace. The single-domain antibody market is rapidly expanding. These antibodies are 1/10th the size of canonical immunoglobulins making them ideal for drug delivery and super-resolution imaging, among many other potential uses. Secondary antibodies for VHH discovery are designed to support research needs, reduce project time and improve success rates.”
Advertisement